摘要:
The present invention relates to a monoclonal antibody specific for N-myc downstream regulated gene 2 (NDRG 2) protein, a cell line producing the monoclonal antibody, a method for measuring a quantity and quality of NDRG 2 protein, and a protein chip using the same. In the present invention, NDRG 2, a cancer-related factor is specifically expressed in dendritic cells differentiated from a monocyte of human peripheral blood. Accordingly, the monoclonal antibody specific for the NDRG 2 protein, the protein chip comprising the same and the method for measuring a quantity and quality of the NDRG 2 protein by using the same can be applied to elucidate characteristics of the dendritic cell and perform a research on the NDRG 2. Therefore, the present invention may help clinically to investigate and treat intractable diseases and cancers using the dendritic cell.
摘要:
An apparatus and method for providing EPG in a digital broadcasting system, in which an EPG connecting unit connects EPG servers of digital broadcasting channels, a program information generating unit generates program information according to program characteristics of the digital broadcasting channels, and an EPG server generates EPG information using the generated program information, and combines the generated EPG information with EPG information of the broadcasting channels. Accordingly, the program information of different broadcasting channels can be searched without switching channels, and quality of the EPG service can be improved. Moreover, users can be allowed to personally configure the EPG, thereby providing the EPG according to characteristics of the users.
摘要:
Disclosed herein is a colorectal cancer marker for diagnosing colorectal cancer based on ESM-I overexpression in tissues, cells or body fluids of colorectal cancer patients. Disclosed also is the use of the colorectal cancer marker in the development of therapeutic agents for cancer and in the diagnosis and treatment of colorectal cancer.
摘要:
The present invention relates to a composition for diagnosing colon cancer. The composition comprises at least one marker for measuring an mRNA or protein expression level of at least one gene specific for colon cancer. It can screen the genes which are overexpressed specifically only in colon cancer tissues or blood. The present invention can quantitatively analyze both the mRNA expression levels of the genes and the expression levels of the proteins encoded by the gene at the same time, thereby diagnosing colon caner of an early stage with a high level of reliability.
摘要:
An apparatus and method for providing subscriber information in a mobile communication system are provided. A database stores registered information containing subscriber information, a scope of persons to view the subscriber information, and an open level for the subscriber information. A wait time information management server stores the subscriber information in the database. Upon request for a call from a calling terminal, the wait time information management server searches for the subscriber information in the database and provides the searched subscriber information according to the open level to an MSC. The MSC sends wait time information based on the subscriber information received from the wait time information management server to the calling terminal.
摘要:
The present invention provides a novel amide derivative of formula (I) and a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising same as an active ingredient.
摘要:
Disclosed herein is a colorectal cancer marker for diagnosing colorectal cancer based on ESM-I overexpression in tissues, cells or body fluids of colorectal cancer patients. Disclosed also is the use of the colorectal cancer marker in the development of therapeutic agents for cancer and in the diagnosis and treatment of colorectal cancer.
摘要:
Provided are a composition for diagnosing cancer or screening an anticancer drug comprising an FLJ25416 gene or an antibody directed to a protein expressed from the FLJ25416 gene, a composition for treating cancer comprising an inhibitor of the gene or an inhibitor of the protein expressed from the gene and a pharmaceutically acceptable carrier, and a kit for diagnosing cancer comprising at least one of the FLJ25416 gene and the protein expressed from the FLJ25416 gene. The FLJ25416 gene is expressed at high level in specific cancer cells, and induces an increase in proliferation rate of normal cells. The expression of the gene is suppressed, which results in an inhibitory effect on cancer cell growth. Thus, the FLJ25416 gene can be used as a target gene for diagnosis or treatment of cancer.